USPTO Examiner SAEED ALI S - Art Unit 1616

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18658011HYDROGEL MEDIUM FOR THE STORAGE AND PRESERVATION OF TISSUEMay 2024April 2025Allow1101NoNo
18583237HUMAN NASAL TURBINATE-DERIVED MESENCHYMAL STEM CELL-BASED, 3D BIOPRINTED CONSTRUCT, AND USE THEREOFFebruary 2024June 2025Allow1610NoNo
18490248Triple Negative Breast Cancer Treatment MethodOctober 2023May 2025Abandon1911NoNo
18163321GLUCONIC ACID DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF MICROBIAL INFECTIONSFebruary 2023October 2024Allow2021YesNo
17977302GUMMY COMPOSITION AND METHODS OF USE THEREOFOctober 2022November 2024Abandon2411NoNo
17893859SCAFFOLD WOUND DRESSINGAugust 2022January 2023Allow510NoNo
17669768AGROCHEMICAL COMPOSITIONFebruary 2022June 2024Allow2850YesNo
17634009AN AGROCHEMICAL COMPOSITIONFebruary 2022April 2025Allow3811YesNo
17595217Microcapsule With A Porous Or Hollow Core And A Shell Containing A Component Releasing Gas Upon Contact With An AcidNovember 2021April 2025Abandon4111YesNo
17391026Nonhormonal Unisex ContraceptivesAugust 2021June 2024Abandon3411NoNo
17371562MODULAR PLANTING MATERIAL FOR NATURAL TURF IN SPORTS FIELD AND ITS MANUFACTURING PROCESSJuly 2021February 2025Abandon4301NoNo
17311706COMPOSITIONS COMPRISING FLORPYRAUXIFEN THAT SAFEN WHITE CLOVER AND METHODS OF USE THEREOFJune 2021September 2024Abandon4001NoNo
17335542CUCURBITURIL MOLECULAR CONTAINERS AND METHODS OF USING SAMEJune 2021January 2025Abandon4321NoNo
17298053COMPOSITION FOR ENHANCING DROUGHT AND OSMOTIC STRESS RESISTANCE, AND THEIR USESMay 2021June 2025Abandon4931NoNo
17296330Immune Supplement CompositionMay 2021June 2025Abandon4931NoNo
17291267COMPOSITIONS COMPRISING PYRIDINE CARBOXYLATE HERBICIDES AND CELLULOSE BIOSYNTHESIS INHIBITOR HERBICIDESMay 2021October 2024Abandon4101NoNo
17291239COMPOSITIONS COMPRISING PYRIDINE CARBOXYLATE HERBICIDES AND FATTY ACID AND LIPID SYNTHESIS INHIBITOR HERBICIDESMay 2021October 2024Abandon4101NoNo
17285833NANOEMULSION CANNABIS FORMULATIONS AND METHODS OF MAKING SAMEApril 2021August 2024Abandon4001NoNo
17220073COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSISApril 2021October 2023Abandon3041YesNo
17281005WOOD PRESERVATIVESMarch 2021June 2025Allow5021NoNo
17213986ANTI-ALLERGENIC OCULAR COMPOSITIONS AND EYELID CLEANSING WIPESMarch 2021October 2024Abandon4311NoNo
17277219HERBICIDALLY ACTIVE SUBSTITUTED PHENYLPYRIMIDINE HYDRAZIDESMarch 2021November 2024Abandon4401NoNo
17176726Galectin-3 Governs and Coordinates ESCRT and Autophagic Responses During Endomembrane DamageFebruary 2021October 2023Abandon3211NoNo
17121558N-Phenylacetyl-L-prolylglycine ethyl ester compositions and methods for using the sameDecember 2020February 2023Abandon2601NoNo
17102257SCAFFOLD WOUND DRESSINGNovember 2020March 2022Allow1631YesNo
17048234ANTIFIBROTIC COMPOSITIONOctober 2020November 2024Abandon4931NoNo
17031889BIOAVAILABLE MINERALS FOR THE MITIGATION OF PATHOGENS IN PLANTSSeptember 2020June 2023Abandon3201NoNo
16958436COMPOSITION COMPRISING FERROUS SULPHATE MONOHYDRATE AND LONG CHAIN POLYUNSATURATED FATTY ACIDSJune 2020March 2024Abandon4540YesNo
16771033Improved Method for Removing Bacterial Biofilms and Treating TissueJune 2020July 2022Abandon2511NoNo
16865529COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MILK THISTLE EXTRACT OR POWDERMay 2020October 2021Allow1811YesNo
16758858BIOCOMPATIBLE SOFT TISSUE IMPLANTApril 2020June 2023Abandon3701NoNo
16753899GLUCONIC ACID DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF MICROBIAL INFECTIONSApril 2020October 2022Allow3121NoNo
16645989TETRAZOLINONE COMPOUND AND USE THEREOFMarch 2020December 2020Allow900YesNo
16798380NOVEL PLANT ESSENTIAL OIL AND WAX FORMULATIONS FOR USE AS PESTICIDES AND PLANT BIOSTIMULANTSFebruary 2020July 2022Abandon2921YesNo
16794870Herbicide Formulations and their UseFebruary 2020October 2021Abandon2030NoNo
16638416SOLVENTS FOR AGRICULTURAL APPLICATIONS AND PESTICIDE FORMULATIONSFebruary 2020September 2021Abandon1920NoNo
16638418SOLVENTS FOR AGRICULTURAL APPLICATIONS AND PESTICIDE FORMULATIONSFebruary 2020January 2023Allow3521YesNo
16773734PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTSJanuary 2020July 2022Allow3011NoNo
16632846NANOSTRUCTURED AND BIOCOMPATIBLE BIOCATALYSTS FOR USE IN CANCER TREATMENTJanuary 2020October 2021Abandon2110NoNo
16630058ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN AMMONIUM COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAMEJanuary 2020June 2024Abandon5341NoYes
16626807FUNGICIDAL COMPOSITIONSDecember 2019July 2023Abandon4321YesNo
16720290ACTIVE INGREDIENT COMBINATIONS COMPRISING PYRIDYLETHYLBENZAMIDES AND OTHER ACTIVE INGREDIENTSDecember 2019October 2022Abandon3411NoNo
16624195COMPOUNDS AND COMPOSITIONS FOR EXTENDING LIFESPAN OF A SUBJECTDecember 2019November 2022Abandon3521NoNo
166240472-[[5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOL-3-YL]ARYLOXY](THIO)ACETAMIDES FOR COMBATING PHYTOPATHOGENIC FUNGIDecember 2019May 2023Abandon4101NoNo
16711616MICROCAPSULES COMPRISING ACTIVE INGREDIENTS AND A METAL OXIDE SHELL, A METHOD FOR THEIR PREPARATION AND USES THEREOFDecember 2019August 2024Abandon5661NoNo
16621159SAFENERS AND FORMULATIONS CONTAINING SAFENERS, BIOCIDES AND INOCULANTSDecember 2019October 2022Abandon3421NoNo
16700114AQUEOUS HERBICIDAL COMPOSITIONS AND METHODS OF USE THEREOFDecember 2019March 2023Allow3961NoNo
16690956HIGH CONCENTRATION PROTEIN FORMULATIONNovember 2019March 2024Allow5141YesYes
16614319LACTONES AS SOLVENTS IN AGROCHEMICAL FORMULATIONSNovember 2019September 2022Abandon3421YesNo
16610100Use of an Acyclic Picolinamide Compound as a Fungicide for Control of Phytopathogenic Fungi in VegetablesNovember 2019August 2024Abandon5750YesNo
16610102Use of an Acyclic Picolinamide Compound as a Fungicide for Control of Phytopathogenic Fungi in Orchard, Vineyard and Plantation CropsNovember 2019August 2024Abandon5740YesYes
16669676COSMETIC COMPOSITION COMPRISING BIODEGRADABLE POLYMERSOctober 2019October 2023Abandon4741NoNo
16609887HUMAN NASAL TURBINATE-DERIVED MESENCHYMAL STEM CELL-BASED, 3D BIOPRINTED CONSTRUCT, AND USE THEREOFOctober 2019November 2023Allow4921YesNo
16604223MESOIONIC IMIDAZOPYRIDINES AS INSECTICIDESOctober 2019October 2022Abandon3601NoNo
16582688NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAMESeptember 2019November 2021Abandon2501NoNo
16497269DROPROPIZINE IN COMBINATION WITH AMBROXOL IN THE DOSAGE FORM OF SYRUP OR TABLETSSeptember 2019April 2024Abandon5541NoNo
16497089WOOD PRESERVATIVESSeptember 2019May 2022Abandon3220YesNo
16568004COMPOSITION COMPRISING HYDROGEN GAS FOR SUPPRESSION OR PREVENTION OF CANCER METASTASISSeptember 2019November 2024Abandon6031NoNo
16561215Nematode Control System and MethodSeptember 2019July 2021Abandon2220NoNo
16555448ORGANIC WEED REMOVERAugust 2019April 2024Abandon5551NoNo
16555231SEED TREATMENT COMPOSITION AND METHOD OF USINGAugust 2019April 2024Abandon5641NoYes
16549043COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSISAugust 2019June 2024Abandon5841NoYes
16485256HYDROGEL MEDIUM FOR THE STORAGE AND PRESERVATION OF TISSUEAugust 2019January 2024Allow5321YesNo
16535964COSMETIC BASE COMPOSITIONS AND ASSOCIATED COSMETIC COMPOSITIONSAugust 2019February 2022Allow3031YesNo
16481606METHOD OF STRENGTHENING HAIRJuly 2019October 2023Abandon5150NoNo
16514586SECNIDAZOLE SOFT GELATIN CAPSULE AND METHODS AND USES THEREOFJuly 2019November 2022Abandon4031YesNo
16508626ANTI-ALLERGENIC OCULAR COMPOSITIONS AND EYELID CLEANSING WIPESJuly 2019December 2020Allow1711YesNo
16504660MICROSPHERICAL PARTICLEJuly 2019March 2022Abandon3220NoNo
16458086SUPPLEMENT PATCHJune 2019August 2024Abandon6070NoNo
16452648METHOD FOR CONTROLLING SAN JOSE SCALEJune 2019May 2023Abandon4740NoYes
16470426TOPICAL SKIN LIGHTENING ADDITIVE AND COMPOSITION WITH AMINO ACIDS AND PPAR ACTIVATING FATTY ACIDSJune 2019December 2024Abandon6050YesNo
16469128ADJUVANTS FOR AGROCHEMICAL FORMULATIONSJune 2019June 2025Allow6080YesYes
16468592ADJUVANTSJune 2019July 2024Abandon6020NoYes
16467097USE OF INSECTICIDES FOR CONTROLLING WIREWORMSJune 2019January 2022Abandon3121YesNo
16465747HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPODS CONTROL AGENT COMPRISING THE SAMEMay 2019December 2022Allow4311NoNo
16427505DRUG DELIVERY ARTICLES FOR GRAM-LEVEL DOSINGMay 2019April 2024Abandon5930NoNo
16423400AQUEOUS HERBICIDAL INTERMIXTURESMay 2019June 2024Allow6051YesNo
16417096Clear or Translucent CompositionMay 2019May 2022Abandon3630NoNo
16336655PARTICULATE SUBSTANCE MIXTURE, PREFERABLY FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A RESPIRATORY DISORDERMarch 2019July 2021Abandon2810NoNo
16362780PLANT GROWTH REGULATOR OF ELEVATING ANTI-STRESS ABILITY AND USE THEREOFMarch 2019October 2023Allow5441YesNo
16361531AQUEOUS NEMATICIDAL COMPOSITIONS CONTAINING DISPERSANTS TO INHIBIT CRYSTAL GROWTHMarch 2019September 2022Abandon4231NoNo
16334136PHARMACEUTICAL COMPOSITIONMarch 2019June 2024Abandon6060NoYes
16329305METHOD OF CONTROLLING FUNGAL INFECTIONS IN PLANTSFebruary 2019July 2023Allow5351YesNo
16283660Topical Compositions and Methods for Treatment of Diabetic NeuropathiesFebruary 2019February 2025Allow6061YesNo
16256784TRANSDERMAL PREPARATIONJanuary 2019November 2020Abandon2210NoNo
16239754PROCESSING COMPOSITION FOR CONTROLLING AQUATIC WEEDSJanuary 2019April 2021Abandon2801NoNo
16215455Compounds, Compositions, and Methods for Altering Insect and Organism BehaviorDecember 2018August 2023Allow5651YesNo
16308664METHOD AND COSMETIC COMPOSITION FOR ENHANCED TRANSDERMAL DELIVERY OF ALKYL SUBSTITUTED RESORCINOLDecember 2018October 2022Abandon4651YesNo
16307423FUNGICIDAL COMPOSITIONDecember 2018August 2021Allow3320YesNo
16306476SEQUENTIAL CLICK REACTIONS FOR THE SYNTHESIS AND FUNCTIONALIZATION OF HYDROGEL MICROSPHERES AND SUBSTRATESNovember 2018April 2021Abandon2811NoNo
16190260METHOD OF PREVENTING MICROBIAL DECAY AND BREAKDOWN OF COSMETIC COMPOSITIONSNovember 2018October 2022Abandon4731NoNo
16181970COMPOSITION AND METHOD FOR AIDING SLEEPNovember 2018April 2022Abandon4130NoNo
16095221Triple Negative Breast Cancer Treatment MethodOctober 2018November 2023Abandon6041YesNo
16093474MEDICAL DEVICE COMPRISING GRAPHENE COATINGOctober 2018December 2024Abandon6051NoNo
16155178METHODS AND COMPOSITIONS FOR CONTROLLING UNDESIRED VEGETATION SUCH AS INVASIVE ANNUAL GRASSESOctober 2018November 2023Abandon6040NoNo
16084526CORE-SHELL PLASMONIC NANOGAPPED NANOSTRUCTURED MATERIALSeptember 2018April 2022Abandon4341NoNo
16053623METHOD OF ENHANCING THE BIODISTRIBUTION AND TISSUE TARGETING PROPERTIES OF THERAPEUTIC CECO2 PARTICLES VIA NANO-ENCAPSULATION AND COATINGAugust 2018February 2021Abandon3101NoNo
16071710OROMUCOSAL NANOFIBER CARRIERS FOR THERAPEUTIC TREATMENTJuly 2018September 2024Allow6061YesNo
16039172Foundation with controllable color changeJuly 2018November 2021Abandon4021NoNo
16067820POLYVINYL ALCOHOL/SODIUM ALGINATE/HYDROXYAPATITE COMPOSITE FIBROUS MEMBRANE, AND PREPARATION METHOD AND APPLICATION THEREOFJuly 2018August 2023Allow6041YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SAEED, ALI S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
2
(66.7%)
Examiner Reversed
1
(33.3%)
Reversal Percentile
48.2%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
12
Allowed After Appeal Filing
2
(16.7%)
Not Allowed After Appeal Filing
10
(83.3%)
Filing Benefit Percentile
16.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SAEED, ALI S - Prosecution Strategy Guide

Executive Summary

Examiner SAEED, ALI S works in Art Unit 1616 and has examined 111 patent applications in our dataset. With an allowance rate of 28.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner SAEED, ALI S's allowance rate of 28.8% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SAEED, ALI S receive 2.83 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SAEED, ALI S is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +44.0% benefit to allowance rate for applications examined by SAEED, ALI S. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 12.3% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 8.2% of cases where such amendments are filed. This entry rate is in the 4% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 11% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 85.7% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.